Mariner’s Humacyte HUMA Stock Holding History

Mariner’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$137K	Buy	174,975 +68,697	+65%	+$63.7K	﹤0.01%	3264
2026 Q1	$64.5K	Buy	+106,278	New	+$110K	﹤0.01%	3395

Other funds holding HUMA

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Mariner's HUMA Position: Q2 2026 in Review

Mariner increased its Humacyte (HUMA) stake by 65% in Q2 2026, buying an estimated $63.7K and bringing the position to 174,975 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #3264.

Mariner first reported a position in HUMA in Q1 2026 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

Mariner held 174,975 shares of Humacyte worth $137K as of Q2 2026.
Mariner bought 68,697 Humacyte shares in Q2 2026, an estimated $63.7K.
Humacyte made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3264 holding.
Mariner first reported a position in Humacyte in Q1 2026 and has held it in 2 quarters since.
161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.